The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.
